Peptide Library / Detail
Survodutide
Half-life
Approximately 1 week (supports once-weekly dosing)
Delivery
Once-weekly subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Survodutide (BI 456906) is a long-acting peptide that co-activates GLP-1 and glucagon receptors, designed to deliver robust body-weight reduction by coupling GLP-1–mediated appetite control with glucagon-driven increases in energy expenditure and hepatic lipid mobilization.
Usage
Studied for chronic weight management and metabolic disease, including obesity and metabolic dysfunction–associated steatohepatitis (MASH).
Mechanism of Action
Agonism at GLP-1R enhances glucose-dependent insulin secretion, slows gastric emptying, reduces appetite, and suppresses inappropriate glucagon; concurrent GCGR activation increases energy expenditure and promotes fatty-acid oxidation. The combined signaling can yield greater weight loss than GLP-1–only agonism.
Benefits(4)
- Clinically meaningful body-weight reduction (once-weekly dosing)
- Improved glycemic and cardiometabolic markers in study populations
- Reductions in liver fat and MASH-related biomarkers in trials
- Potential improvements in waist circumference and lipid parameters
Side Effects(5)
- Class-typical GI effects (nausea, vomiting, diarrhea/constipation)
- Decreased appetite
- Injection-site reactions
- Possible mild heart-rate increase (glucagon component, dose-dependent)
- Rare: gallbladder disease or pancreatitis (incretin class consideration)